Chemotherapy News and Research

Latest Chemotherapy News and Research

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Set of genes appear to predict which tumors can evade detection by immune system

Set of genes appear to predict which tumors can evade detection by immune system

Researchers identify genes that appear to predict tumors that can evade detection by immune system

Researchers identify genes that appear to predict tumors that can evade detection by immune system

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Chemotherapy induces long-lasting epigenetic changes in survivors' blood cells

Chemotherapy induces long-lasting epigenetic changes in survivors' blood cells

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Ambit to provide overview of quizartinib drug candidate at Barclays Global Healthcare Conference

Ambit to provide overview of quizartinib drug candidate at Barclays Global Healthcare Conference

UNM physician performs TORS procedure on patient with stage IV throat cancer

UNM physician performs TORS procedure on patient with stage IV throat cancer

LUNGevity Foundation awarded grant to develop educational materials on immuno-oncology

LUNGevity Foundation awarded grant to develop educational materials on immuno-oncology

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

Dendreon plans to make PROVENGE available in Europe

Dendreon plans to make PROVENGE available in Europe

Microencapsulated drug delivery may soon revolutionize cancer treatment

Microencapsulated drug delivery may soon revolutionize cancer treatment

Scientists uncover key mechanism of gene regulation

Scientists uncover key mechanism of gene regulation

Light-activated drug delivery holds promise for treating cancer

Light-activated drug delivery holds promise for treating cancer

Study establishes innovative approaches to improve vision of young children with brain tumor

Study establishes innovative approaches to improve vision of young children with brain tumor

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.